430 related articles for article (PubMed ID: 35032495)
1. Cannabidiol and substance use disorder: Dream or reality.
Karimi-Haghighi S; Razavi Y; Iezzi D; Scheyer AF; Manzoni O; Haghparast A
Neuropharmacology; 2022 Apr; 207():108948. PubMed ID: 35032495
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol in the context of substance use disorder treatment: A systematic review.
Paulus V; Billieux J; Benyamina A; Karila L
Addict Behav; 2022 Sep; 132():107360. PubMed ID: 35580370
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms.
Calpe-López C; García-Pardo MP; Aguilar MA
Molecules; 2019 Jul; 24(14):. PubMed ID: 31315244
[TBL] [Abstract][Full Text] [Related]
4. Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders.
Navarrete F; García-Gutiérrez MS; Gasparyan A; Austrich-Olivares A; Manzanares J
Front Pharmacol; 2021; 12():626010. PubMed ID: 34093179
[TBL] [Abstract][Full Text] [Related]
5. Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage.
Hurd YL; Yoon M; Manini AF; Hernandez S; Olmedo R; Ostman M; Jutras-Aswad D
Neurotherapeutics; 2015 Oct; 12(4):807-15. PubMed ID: 26269227
[TBL] [Abstract][Full Text] [Related]
6. Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals.
Galaj E; Xi ZX
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374481
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Effects of Cannabidiol on Methamphetamine Abuse: A Review of Preclinical Study.
Razavi Y; Keyhanfar F; Shabani R; Haghparast A; Mehdizadeh M
Iran J Pharm Res; 2021; 20(4):152-164. PubMed ID: 35194436
[TBL] [Abstract][Full Text] [Related]
8. The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder.
Chye Y; Christensen E; Solowij N; Yücel M
Front Psychiatry; 2019; 10():63. PubMed ID: 30837904
[TBL] [Abstract][Full Text] [Related]
9. Could Cannabidiol Be a Treatment for Coronavirus Disease-19-Related Anxiety Disorders?
O'Sullivan SE; Stevenson CW; Laviolette SR
Cannabis Cannabinoid Res; 2021; 6(1):7-18. PubMed ID: 33614948
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol Use for Fibromyalgia: Prevalence of Use and Perceptions of Effectiveness in a Large Online Survey.
Boehnke KF; Gagnier JJ; Matallana L; Williams DA
J Pain; 2021 May; 22(5):556-566. PubMed ID: 33400996
[TBL] [Abstract][Full Text] [Related]
11. Cannabidiol goes nuclear: The role of PPARγ.
Khosropoor S; Alavi MS; Etemad L; Roohbakhsh A
Phytomedicine; 2023 Jun; 114():154771. PubMed ID: 36965374
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders.
Yousaf M; Chang D; Liu Y; Liu T; Zhou X
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956911
[TBL] [Abstract][Full Text] [Related]
13. Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
Elsaid S; Kloiber S; Le Foll B
Prog Mol Biol Transl Sci; 2019; 167():25-75. PubMed ID: 31601406
[TBL] [Abstract][Full Text] [Related]
14. Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review.
Singh K; Bhushan B; Chanchal DK; Sharma SK; Rani K; Yadav MK; Porwal P; Kumar S; Sharma A; Virmani T; Kumar G; Noman AA
Behav Neurol; 2023; 2023():8825358. PubMed ID: 37868743
[TBL] [Abstract][Full Text] [Related]
15. Cannabidiol prevents priming- and stress-induced reinstatement of the conditioned place preference induced by cocaine in mice.
Calpe-López C; Gasparyan A; Navarrete F; Manzanares J; Miñarro J; Aguilar MA
J Psychopharmacol; 2021 Jul; 35(7):864-874. PubMed ID: 33427014
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory effect of cannabidiol on the rewarding properties of methamphetamine in part mediates by interacting with the hippocampal D1-like dopamine receptors.
Mohammadi M; Eskandari K; Azizbeigi R; Haghparast A
Prog Neuropsychopharmacol Biol Psychiatry; 2023 Aug; 126():110778. PubMed ID: 37100273
[TBL] [Abstract][Full Text] [Related]
17. Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.
Zavala-Tecuapetla C; Luna-Munguia H; López-Meraz ML; Cuellar-Herrera M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555823
[TBL] [Abstract][Full Text] [Related]
18. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Assessment of the Abuse Potential of Purified Botanical Cannabidiol: Self-Administration, Drug Discrimination, and Physical Dependence.
Gray RA; Heal DJ; Maguire DR; Gerak LR; Javors MA; Smith S; France CP
J Pharmacol Exp Ther; 2022 Jul; 382(1):54-65. PubMed ID: 35489780
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol Adverse Effects and Toxicity.
Huestis MA; Solimini R; Pichini S; Pacifici R; Carlier J; Busardò FP
Curr Neuropharmacol; 2019; 17(10):974-989. PubMed ID: 31161980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
